Following coronary revascularisation surgery
Conditions
Interventions
Experimental Group:Standardized Western medical treatment + Qidan Xiao Ke Granules
Control Group:Standardized Western medical treatment + Qidanshaoke granules placebo
Sponsors
The Third Affiliated Hospital of Zhejiang University of Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Age: 18-80 years old; 2. no gender limitation; 3. Meets the diagnostic criteria for coronary heart disease; 4. Accepts effective PCI procedure; 5. Voluntarily participates and signs a written informed consent form.
Exclusion criteria
Exclusion criteria: 1. Severe hepatic and/or renal insufficiency 2. Severe electrolyte disorders 3. Severe hematological diseases or malignant tumors 4. Pregnant or breastfeeding women 5. Patients with mental illness 6. Cognitive impairment (e.g., dementia, post-stroke cognitive impairment) leading to inability to communicate normally 7. Planning to undergo another revascularization surgery in the near future 8. Other severe cardiovascular diseases (e.g., uncontrolled hypertension, angina pectoris, rapid arrhythmias, high-degree or complete atrioventricular block without a pacemaker implanted, acute severe aortic stenosis, decompensated heart failure (NYHA Class IV), deep vein thrombosis, obstructive hypertrophic cardiomyopathy, acute pericarditis or myocarditis, acute endocarditis, acute aortic dissection, etc.) 9. Acute pulmonary embolism and chronic lung diseases with dyspnea symptoms (occurring at rest or with minimal exertion) 10. Explicit exclusion criteria (bleeding history within 1 month, active bleeding, bleeding tendency, currently using anticoagulants) 11. Participants in other interventional clinical trials within the past month 12. Allergy to known components of the investigational drug (Qidan Xiaohe Granules) 13. Other conditions deemed unsuitable for participation in the trial by the investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The incidence rate of major cardiovascular adverse events; | — |
Secondary
| Measure | Time frame |
|---|---|
| TCM Syndrome Score;Echocardiogram;Dynamic Electrocardiogram;Minnesota Quality of Life Scale;Cardiac enzymes;blood lipids;Blood Glucose; | — |
Countries
China
Contacts
Public ContactLiu Qiang
The Third Affiliated Hospital of Zhejiang University of Chinese Medicine
Outcome results
None listed